Teclistamab for severe lung disease linked to MDA5 antibodies
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether a new drug called teclistamab can help people with a rare, aggressive lung disease caused by MDA5 antibodies. The disease hasn't improved after standard treatments, and this trial is looking for people who need urgent help with breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MDA5 antibodies in your blood (confirmed by a blood test)
- You have lung disease confirmed by a chest CT scan
- Your symptoms started less than 3 months ago
- Your breathing is getting worse and you need extra oxygen or a breathing machine
- Your condition didn't improve after at least 7 days of strong steroids plus two other immune-suppressing drugs
- You are 18 or older and covered by French social security
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
This trial tests a combination of teclistamab (an immunotherapy) and your own immune cells to treat multiple myeloma that has come back or stopped responding to prior treatments. It is for people who have had 1 or 2 prior lines of therapy and have not received a BCMA-targeted treatment before.
Hear when a new Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.